Optimizing extended adjuvant endocrine therapy in patients with breast cancer: a registry-based randomized clinical trial

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506135-14-00

Enrollment

3832

Registered

2023-10-12

Start date

2025-09-10

Completion date

Unknown

Last updated

2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Brief summary

Overall survival

Detailed description

Invasive disease-free survival; distant disease-free survival; breast cancer-specific survival; toxicity (grade 3 or 4); quality of Life; adherence; healthcare resource utilization; sick leave and early retirement

Interventions

DRUGEXEMESTANE

DRUGANASTROZOLE

DRUGTAMOXIFEN

DRUGLETROZOLE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Invasive disease-free survival; distant disease-free survival; breast cancer-specific survival; toxicity (grade 3 or 4); quality of Life; adherence; healthcare resource utilization; sick leave and early retirement	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026